Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
University of Utah climate prize winner develops enzyme to cut cattle methane emissions by half sltrib.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sltrib.com Daily Mail and Mail on Sunday newspapers.
Lumen Bioscience developed an enzyme that targets the methane-producing microorganisms in a cow’s digestive system. Cow burps are a major source of methane, a…